Results 11 to 20 of about 77,108 (288)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Journal of Clinical Oncology, 2021
PURPOSE In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes.
J. Wolchok, V. Chiarion-Sileni, R. Gonzalez, J. Grob, P. Rutkowski, C. Lao, C. Cowey, D. Schadendorf, J. Wagstaff, R. Dummer, P. Ferrucci, M. Smylie, M. Butler, A. Hill, I. Márquez-Rodas, J. Haanen, M. Guidoboni, M. Maio, P. Schöffski, M. Carlino, C. Lebbé, G. McArthur, P. Ascierto, G. Daniels, G. Long, T. Bas, C. Ritchings, J. Larkin, F. Hodi   +28 more
semanticscholar   +1 more source

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

New England Journal of Medicine, 2022
BACKGROUND Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit.
M. Rohaan, T. H. Borch, J. H. van den Berg, Ö. Met, R. Kessels, M. G. Geukes Foppen, J. Stoltenborg Granhøj, B. Nuijen, C. Nijenhuis, I. Jedema, M. van Zon, Saskia Scheij, J. Beijnen, Marten Hansen, C. Voermans, I. M. Noringriis, T. Monberg, R. Holmstroem, L. Wever, M. V. VAN DIJK, L. Grijpink-Ongering, Ludy H.M. Valkenet, A. Torres Acosta, M. Karger, J. Borgers, Renske M T ten Ham, V. Retèl, W. V. van Harten, F. Lalezari, H. van Tinteren, A. V. D. van der Veldt, G. Hospers, Marion A. Stevense-den Boer, K. Suijkerbuijk, M. Aarts, D. Piersma, A. van den Eertwegh, J. D. de Groot, G. Vreugdenhil, E. Kapiteijn, M. Boers-Sonderen, W. Fiets, F. van den Berkmortel, E. Ellebaek, L. Hölmich, A. V. Van Akkooi, W. V. van Houdt, M. Wouters, J. V. van Thienen, C. Blank, A. Meerveld-Eggink, S. Klobuch, S. Wilgenhof, T. Schumacher, M. Donia, I. Svane, J. Haanen   +56 more
semanticscholar   +1 more source

Ipilimumab [PDF]

Drugs in R&D, 2010
Ipilimumab (BMS734016; MDX 101; MDX-010; MDX-CTLA-4; MDX-CTLA4) is an anti-CTLA-4 monoclonal antibody, which is in development by Medarex Inc. and Bristol-Myers Squibb as treatment for malignant melanoma, prostate cancer, lymphoma, and lung cancer. It is currently in phase III development for the melanoma and prostate cancer indications, and phase II ...
openaire   +2 more sources

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

Clinical and Translational Science, 2023
This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib‐experienced patients with hepatocellular carcinoma (HCC).
Bruno Sangro, Thomas Yau, Anthony B. El‐Khoueiry, Masatoshi Kudo, Yun Shen, Marina Tschaika, Amit Roy, Yan Feng, Ling Gao, Urvi Aras   +9 more
doaj   +1 more source

The price of tumor control [PDF]

, 2013
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.
Bergmann, Tanja, Berking, Carola, Bockmeyer, Clemens L., Dummer, Reinhard, Eigentler, Thomas, Fluck, Michael, Garbe, Claus, Goldinger, Simone M., Grabbe, Stephan, Gutzmer, Ralf, Göppner, Daniela, Hauschild, Axel, Hein, Rüdiger, Heinzerling, Lucie M., Hundorfean, Gheorghe, Justich, Armin, Kaehler, Katharina C., Keller, Ullrich, Klein, Christina, Loquai, Carmen, Mateus, Christine, Mohr, Peter, Moos, Roger von, Paetzold, Sylvie, Robert, Caroline, Satzger, Imke, Schadendorf, Dirk, Schlaeppi, Marc, Schuler, Gerold, Schuler-Thurner, Beatrice, Trefzer, Uwe, Ulrich, Jens, Vaubel, Julia, Voskens, Caroline J., Weder, Patrik, Wilhelm, Tabea   +35 more
core   +1 more source

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Journal of Clinical Oncology, 2022
PURPOSE Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory ...
M. Atkins, Sandra J. Lee, B. Chmielowski, A. Tarhini, G. Cohen, T. Truong, H. Moon, D. Davar, M. O'Rourke, J. Stephenson, B. Curti, W. Urba, J. Brell, P. Funchain, K. Kendra, A. Ikeguchi, A. Jaslowski, C. Bane, Mark Taylor, Madhuri Bajaj, R. Conry, Robert J Ellis, T. Logan, N. Laudi, J. Sosman, David G. Crockett, A. Pecora, I. Okazaki, S. Reganti, S. Chandra, S. Guild, Helen X. Chen, H. Streicher, J. Wolchok, A. Ribas, J. Kirkwood   +35 more
semanticscholar   +1 more source

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

Journal for ImmunoTherapy of Cancer, 2022
Background Acral melanoma is a rare melanoma subtype with poor prognosis. Importantly, these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the anti-programmed cell death protein-1 (PD-1 ...
Bart Neyns, Lisa Zimmer, Caroline Robert, Celeste Lebbe, Olivier Michielin, Omid Hamid, Anne Zaremba, Oliver Klein, Ruth Plummer, Joanna Mangana, Paolo A Ascierto, Katharina C Kähler, Georgina V Long, Ryan Sullivan, Grant A McArthur, Michael Weichenthal, Egle Ramelyte, Meghan J Mooradian, Douglas B Johnson, Alexander Shoushtari, Christian U Blank, Judith M Versluis, Prachi Bhave, Claudia Trojanello, Lu Si, Inderjit Mehmi, Tasnia Ahmed, Alexander M Menzies, Adnan Khattak, Severine Roy, Matteo S Carlino, Paul C Lorigan, Clara Allayous, Rachel Roberts-Thomson, Florentia Dimitriou, Kathleen Batty, Thierry Lesimple, Serigne N Lo, Alexandre Wicky, Richard Heywood, Lena Tran, Anna Stansfeld, Julia K Schwarze, Andrea Maurichi, Hui-Ling Yeoh, Mario Santinami, Andrew M Haydon   +46 more
doaj   +1 more source

Phase I Study of Ipilimumab Combined with Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients with Brain Metastases [PDF]

, 2018
Purpose: We performed a phase I study to determine the maximum tolerable dose (MTD) and safety of ipilimumab with stereotactic radiosurgery (SRS) or whole brain radiotherapy (WBRT) in patients with brain metastases (BM) from melanoma.
Andrews MD, David W., Daskalakis, Constantine, Dicker, Adam, MD, PhD, Eldredge-Hindy, Harriet B., Evans, James J., Farrell, MD, Christopher J, Feeney, Kendra J., Garg, Shivank, Judy, MD, Kevin, Kendra, Kari L., Kim, Lyndon, Kim, MD, Hyun, Liebner, David A., Mastrangelo, Michael, Olencki, Thomas, Palmer, Joshua D., Sato, Takami, Shi, Wenyin, Werner-Wasik, Maria, Williams, Noelle L., Wuthrick, Evan J.   +20 more
core   +2 more sources

Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels

Frontiers in Oncology, 2014
Stage IV metastatic melanoma patients historically have a poor prognosis with 5-10% 5-year survival. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA4), is one of the first treatments to provide beneficial durable ...
Anna M. Leung, Agnes Fermin Lee, Junko eOzao-Choy, Romela Irene Ramos, Omid eHamid, Steven J. O'Day, Myung eShin-Sim, Donald L. Morton, Mark B. Faries, Peter A. Sieling, Delphine J Lee   +10 more
doaj   +1 more source

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada

BMC Cancer, 2020
Background For novel cancer treatments, effectiveness in clinical practice is not always aligned with clinical efficacy results. As such it is important to understand a treatment’s real-world effectiveness.
Wei Fang Dai, Jaclyn M. Beca, Ruth Croxford, Wanrudee Isaranawatchai, Ines B. Menjak, Teresa M. Petrella, Nicole Mittmann, Craig C. Earle, Scott Gavura, Timothy P. Hanna, Kelvin K.W. Chan   +10 more
doaj   +1 more source